國立高雄大學圖資館 |

登入

回首頁

Data science, AI, and machine learning in drug development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Data science, AI, and machine learning in drug developmentedited by Harry Yang.
其他作者:	Yang, Harry.
出版者:	Boca Raton, FL :Chapman & Hall/CRC Press,2023.
面頁冊數:	1 online resource (xiv, 320 p.)
標題:	Drug developmentData processing.
電子資源:	https://www.taylorfrancis.com/books/9781003150886
ISBN:	9781003150886$q(electronic bk.)

Data science, AI, and machine learning in drug development
Data science, AI, and machine learning in drug development[electronic resource] /edited by Harry Yang. - 1st ed. - Boca Raton, FL :Chapman & Hall/CRC Press,2023. - 1 online resource (xiv, 320 p.) - Chapman & Hall/CRC bostatistics series. - Chapman & Hall/CRC biostatistics series..

Includes bibliographical references and index.

Chapter 1 Transforming Pharma with Data Science, AI and Machine Learning -- Chapter 2 Regulatory Perspective on Big Data, AI, and Machining Learning -- Chapter 3 Building an Agile and Scalable Data Science Organization -- Chapter 4 AI and Machine Learning in Drug Discovery -- Chapter 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing -- Chapter 6 AI-Enabled Clinical Trials -- Chapter 7 Machine Learning for Precision Medicine -- Chapter 8 Reinforcement Learning in Personalized Medicine -- Chapter 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance -- Chapter 10 Intelligent Manufacturing and Supply of Biopharmaceuticals -- Chapter 11 Reinventing Medical Affairs in the Era of Big Data and Analytics -- Chapter 12 Deep Learning with Electronic Health Record -- Chapter 13 Real-World Evidence for Treatment Access and Payment Decisions.

The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise

ISBN: 9781003150886$q(electronic bk.)Subjects--Topical Terms:

610859
Drug development
--Data processing.

LC Class. No.: RM301.25

Dewey Class. No.: 615.1/900285

Data science, AI, and machine learning in drug development
LDR:03673cmm a2200373 a 4500 001 682190
005 20251017072503.0
006 m o d
007 cr cnu---unuuu
008 251202s2023 flu ob 001 0 eng d
020 $a 9781003150886$q(electronic bk.)
020 $a 1003150888$q(electronic bk.)
020 $a 9781000652673$q(electronic bk. : PDF)
020 $a 100065267X$q(electronic bk. : PDF)
020 $a 9781000652697$q(electronic bk. : EPUB)
020 $a 1000652696$q(electronic bk. : EPUB)
020 $z 9780367714413$q(pbk.)
020 $z 9780367708078$q(hbk.)
035 $a (OCoLC)1342002591
035 $a (OCoLC-P)1342002591
035 $a 9781003150886
040 $a OCoLC-P $b eng $c OCoLC-P
041 0 $a eng
050 4 $a RM301.25
082 0 4 $a 615.1/900285 $2 23
245 0 0 $a Data science, AI, and machine learning in drug development $h [electronic resource] / $c edited by Harry Yang.
250 $a 1st ed.
260 $a Boca Raton, FL : $b Chapman & Hall/CRC Press, $c 2023.
300 $a 1 online resource (xiv, 320 p.)
490 1 $a Chapman & Hall/CRC bostatistics series
504 $a Includes bibliographical references and index.
505 0 $a Chapter 1 Transforming Pharma with Data Science, AI and Machine Learning -- Chapter 2 Regulatory Perspective on Big Data, AI, and Machining Learning -- Chapter 3 Building an Agile and Scalable Data Science Organization -- Chapter 4 AI and Machine Learning in Drug Discovery -- Chapter 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing -- Chapter 6 AI-Enabled Clinical Trials -- Chapter 7 Machine Learning for Precision Medicine -- Chapter 8 Reinforcement Learning in Personalized Medicine -- Chapter 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance -- Chapter 10 Intelligent Manufacturing and Supply of Biopharmaceuticals -- Chapter 11 Reinventing Medical Affairs in the Era of Big Data and Analytics -- Chapter 12 Deep Learning with Electronic Health Record -- Chapter 13 Real-World Evidence for Treatment Access and Payment Decisions.
520 $a The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise
588 $a OCLC-licensed vendor bibliographic record.
650 0 $a Drug development $x Data processing. $3 610859
650 0 $a Artificial intelligence. $3 194058
650 0 $a Machine learning. $3 188639
700 1 $a Yang, Harry. $3 825669
830 0 $a Chapman & Hall/CRC biostatistics series. $3 508409
856 4 0 $u https://www.taylorfrancis.com/books/9781003150886